Abstract:Summary Background Accurate tumour response prediction to targeted therapy allows for personalised conversion therapy for patients with unresectable colorectal cancer liver metastases (CRLM). In this study, we aimed to develop and validate a multi-modal deep learning model to predict the efficacy of bevacizumab in patients with initially unresectable CRLM using baseline PET/CT, clinical data, and colonoscopy biopsy specimens. Methods In this multicentre cohort study, we retrospectively collected data of 307 patients with CRLM from the BECOME study ( NCT01972490 ) (Zhongshan Hospital of Fudan University, Shanghai) and two independent Chinese cohorts (internal validation cohort from January 1, 2018 to December 31, 2018 at Zhongshan Hospital of Fudan University; external validation cohort from January 1, 2020 to December 31, 2020 at Zhongshan Hospital—Xiamen, Shanghai, and the First Hospital of Wenzhou Medical University, Wenzhou). The main inclusion criteria were that patients with CRLM had pre-treatment PET/CT images as well as colonoscopy specimens. After extracting PET/CT features with deep neural networks (DNN) and selecting related clinical factors using LASSO analysis, a random forest classifier was built as the Deep Radiomics Bevacizumab efficacy predicting model (DERBY). Furthermore, by combining histopathological biomarkers into DERBY, we established DERBY + . The performance of model was evaluated using area under the curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value. Findings DERBY achieved promising performance in predicting bevacizumab sensitivity with an AUC of 0.77 and 95% confidence interval (CI) [0.67–0.87]. After combining histopathological features, we developed DERBY + , which had more robust accuracy for predicting tumour response in external validation cohort (AUC 0.83 and 95% CI [0.75–0.92], sensitivity 80.4%, specificity 76.8%). DERBY + also had prognostic value: the responders had longer progression-free survival (median progression-free survival: 9.6 vs 6.3 months, p = 0.002) and overall survival (median overall survival: 27.6 vs 18.5 months, p = 0.010) than non-responders. Interpretation This multi-modal deep radiomics model, using PET/CT, clinical data and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favourable approach for precise patient treatment. To further validate and explore the clinical impact of this work, future prospective studies with larger patient cohorts are warranted. Funding The National Natural Science Foundation of China ; Fujian Provincial Health Commission Project ; Xiamen Science and Technology Agency Program ; Clinical Research Plan of SHDC ; Shanghai Science and Technology Committee Project ; Clinical Research Plan of SHDC ; Zhejiang Provincial Natural Science Foundation of China ; and National Science Foundation of Xiamen .

Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib Plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study

CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma after Surgical Resection

Radiomics Model Based on Intratumoral and Peritumoral Features for Predicting Major Pathological Response in Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy

Enhanced Rim On Mdct Of Colorectal Liver Metastases: Assessment Of Ability To Predict Progression-Free Survival And Response To Bevacizumab-Based Chemotherapy

Prediction of Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive Imaging Method

Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy

Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases

Identifying Response in Colorectal Liver Metastases Treated with Bevacizumab: Development of RECIST by Combining Contrast-Enhanced and Diffusion-Weighted MRI

Treatment response assessment to chemotherapy with bevacizumab for colorectal liver metastasis by contrast-enhanced ultrasound

Pre-operative prediction of histopathological growth patterns of colorectal cancer liver metastasis using MRI-based radiomic models

Identification of Predominant Histopathological Growth Patterns of Colorectal Liver Metastasis by Multi-Habitat and Multi-Sequence Based Radiomics Analysis

Baseline hepatobiliary MRI for predicting chemotherapeutic response and prognosis in initially unresectable colorectal cancer liver metastases

Radiomics analysis based on contrast-enhanced MRI for predicting short-term efficacy of drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma

Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study

Association of CT-Based Delta Radiomics Biomarker With Progression-Free Survival in Patients With Colorectal Liver Metastases Undergo Chemotherapy

Prediction of Transformation in the Histopathological Growth Pattern of Colorectal Liver Metastases after Chemotherapy Using CT-based Radiomics.

Rim enhancement on hepatobiliary phase of pre-treatment 3.0 T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX

Deep learning‐based radiomics predicts response to chemotherapy in colorectal liver metastases

Radiomics and machine learning analysis of liver magnetic resonance imaging for prediction and early detection of tumor response in colorectal liver metastases

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer